GlassScriptPhysician profile
Margo R Steed
NPI 1760103915
$4,903.07
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $30.01 · 2023: $2,611 · 2024: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,873.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $887.74 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $800.02 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $768.89 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $533.17 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $495.01 | 2023-2024 | Mounjaro, Lyumjev, Zepbound |
| Amgen INC. | $302.85 | 2023 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $146.09 | 2024 | |
| Astellas Pharma US INC | $133.83 | 2023-2024 | Veozah |
| Exact Sciences Corporation | $128.18 | 2023-2024 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
| Grifols USA, LLC | $119.70 | 2024 | Prolastin-C Liquid |
| Medtronic, INC. | $100.69 | 2023 | Endurant Iis |
| Pfizer INC. | $86.91 | 2023-2024 | |
| Dexcom, INC. | $85.07 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $57.54 | 2024 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $37.56 | 2024 | Flucelvax, Fluad |
| Abbott Laboratories | $21.72 | 2024 | Freestyle Libre |
| Novavax INC | $19.95 | 2023 | Novavax Covid-19 Vaccine, Adjuvanted |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.59 | 2024 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $17.55 | 2023 | |
| Insulet Corporation | $17.02 | 2023 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margo Steed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.